Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$2.78
$0.10(3.73%)
At close: 4:00 PM EDT
$2.78
$0.10(3.73%)
Day’s Range― - ―
52-Week Range$1.31 - $18.90
Previous CloseN/A
Volume38.05K
Average Volume (3M)102.19K
Market Cap
$6.15M
Enterprise Value-$2.13
Total Cash (Recent Filing)$4.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 19, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.78
Shares Outstanding2,188,469
10 Day Avg. Volume29,103
30 Day Avg. Volume102,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.00Price Target Upside151.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage / Balance Sheet StrengthZero reported debt materially lowers refinancing and interest-rate exposure for a development-stage biotech. That structural liquidity advantage provides flexibility to fund trials or negotiate financing terms without immediate interest burden, preserving runway and strategic optionality.
Strategic Pipeline And Financing From Azora MergerThe Azora acquisition brings a new early-stage IBD asset (AT177), senior scientific hires, and up to $64M in committed financing. This is a structural repositioning from alcohol use disorder to inflammation, expanding the long-term R&D runway and diversifying the development portfolio.
Improving Cash Burn TrendAlthough still negative, a measurable improvement in free cash flow burn versus prior years indicates management is reducing cash consumption per period. That durable trend lessens near-term funding needs and improves the odds of reaching development inflection points with less dilution.
Bears Say
Pre-revenue Operations With Sustained LossesBeing pre-revenue with multi-million dollar recurring losses is a structural constraint: the company must fund R&D and operations externally until commercialization. This long-duration value realization raises execution risk and prolongs reliance on capital markets or partners.
Negative Operating And Free Cash Flow Requiring External CapitalPersistent negative operating and free cash flow means the company lacks self-sustaining cash generation. Over a multi-month horizon this structurally increases refinancing, dilution, or partner-dependency risks if development timelines extend or milestones slip.
Governance And Dilution Risk From Merger TermsCreating a new preferred class and issuing conversion-linked securities materially changes capital structure and control. These durable changes can dilute common shareholders, alter decision-making incentives, and create conversion-linked overhang that affects future financing flexibility.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharma’s price range in the past 12 months?
Adial Pharma lowest stock price was $1.31 and its highest was $18.90 in the past 12 months.
What is Adial Pharma’s market cap?
Adial Pharma’s market cap is $6.15M.
When is Adial Pharma’s upcoming earnings report date?
Adial Pharma’s upcoming earnings report date is Aug 19, 2026 which is in 20 days.
How were Adial Pharma’s earnings last quarter?
Adial Pharma released its earnings results on May 11, 2026. The company reported -$1.48 earnings per share for the quarter, beating the consensus estimate of -$2.73 by $1.25.
Is Adial Pharma overvalued?
According to Wall Street analysts Adial Pharma’s price is currently Undervalued.
Does Adial Pharma pay dividends?
Adial Pharma does not currently pay dividends.
What is Adial Pharma’s EPS estimate?
Adial Pharma’s EPS estimate is -1.02.
How many shares outstanding does Adial Pharma have?
Adial Pharma has 2,188,469 shares outstanding.
What happened to Adial Pharma’s price movement after its last earnings report?
Adial Pharma reported an EPS of -$1.48 in its last earnings report, beating expectations of -$2.73. Following the earnings report the stock price went up 0.699%.
Which hedge fund is a major shareholder of Adial Pharma?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharma
Adial Pharmaceuticals, Inc. (ADIL) is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment and prevention of addiction and related disorders, with an initial focus on alcohol use disorder. The company’s lead product candidate is AD04, which it has positioned as a genetically targeted treatment approach in alcohol use disorder, and it also operates a companion diagnostics effort intended to identify patient subgroups more likely to respond to therapy.
ADIL Stock 12 Month Forecast
Average Price Target
$7.00
▲(151.80% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
36.13% Insiders
0.29% Mutual Funds
0.37% Other Institutional Investors
62.95% Public Companies and
Individual Investors